• Username (E-mail)
  • Password
Dow 20,810 0.2%  EStoxx50 3,289 -1.4%  Nikkei 19,284 -0.5%  EUR 1.0609 0.3% 
Nasdaq 5,836 -0.4%  FTSE100 7,217 -0.8%  Yen 112.2350 -0.4%  Oil 56.1 -0.7% 
S&P500 2,364 0.0%  DAX 11,749 -1.7%  GBP 1.2555 0.0%  Gold 1,257 0.6% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

Estimates* for Vertex Pharmaceuticals Inc. in USD

  2015 2016 2017 2018 2019 2020 2021
Revenue 1,702.17 1,996.99 2,559.84 3,226.41 3,874.13 4,222.72
Dividend 0.00 0.00 0.00 0.00
Dividend Yield (in %) % % % % % % %
EPS 0.85 1.61 2.98 4.58 5.89 6.50
P/E Ratio -53.89 99.27 55.66 30.02 19.56 15.21 13.78
EBIT 9.94 185.36 615.16 1,153.51 1,684.30 2,222.36
EBITDA 69.88 335.48 683.43 1,013.81 1,396.83 1,784.07
Net Profit 211.20 396.87 791.82 1,318.10 1,707.89 1,650.13
Net Profit Adjusted 211.20 396.87 791.82 1,318.10 1,707.89 1,650.13
Pre-Tax Profit -67.37 128.86 593.44 1,009.98 1,476.28 2,403.61
Net Profit (Adjusted) -69.36 126.54 421.36 725.73
EPS (Clean) 0.85 1.61 2.98 4.58 5.89 6.50
EPS (Reported) -0.46 0.60 1.95 3.58 4.39 4.93
Gross Income 1,495.00 1,740.85 2,328.48 3,057.61 3,666.85 4,086.52
Cash Flow from Investing -64.97 68.73 -68.45 -97.31 -219.79 -298.02
Cash Flow from Operations 215.00 507.94 754.37 1,043.67 1,558.59 1,929.38
Cash Flow from Financing 46.53 -1.16 -27.08 51.54 78.36 79.48
Cash Flow per Share 0.78 1.71 1.49 3.12
Free Cash Flow 153.00 436.29 475.36 840.81 1,231.78 1,591.97
Free Cash Flow per Share 0.61 0.89 1.30 2.89
Book Value per Share 4.52 5.96 8.26 11.39 19.79 26.24
Net Debt -795.26 -1,455.46 -1,699.68 -2,237.06
Research & Development Exp. 1,047.69 1,100.76 1,163.93 1,209.00 1,201.51 1,191.47
Capital Expenditure 59.28 64.47 89.50 124.67 259.65 336.84
Selling, General & Admin. Exp. 432.83 484.10 531.52 567.78 600.33 623.16
Shareholder’s Equity 1,338.19 1,850.92 2,217.91 3,071.24 4,949.16 6,622.09
Total Assets 2,894.00 3,547.39 4,047.40 5,037.92 6,994.09 8,685.49
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet